(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

ClinicalTrials.gov ID: NCT04910685

Public ClinicalTrials.gov record NCT04910685. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Apr 22, 2026, 8:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis

Study identification

NCT ID: NCT04910685
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2, Phase 3
Lead sponsor: Blueprint Medicines Corporation; Industry
Enrollment: 534 participants

Conditions and interventions

Conditions

Interventions

Elenestinib Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 29, 2021
Primary completion: Sep 29, 2032
Completion: Sep 29, 2032
Last update posted: Apr 19, 2026

2021 – 2032

United States locations

U.S. sites: 14
U.S. states: 12
U.S. cities: 14

Facility	City	State	ZIP	Site status
University of Alabama at Birmingham	Birmingham	Alabama	35294	Recruiting
David Geffen School of Medicine at UCLA	Los Angeles	California	90095	Recruiting
Stanford Cancer Institute	Palo Alto	California	94305	Recruiting
UCHealth Blood Disorders and Cell Therapies Center - Anschutz Medical Campus	Aurora	Colorado	80045	Recruiting
Winship Cancer Institute, Emory University	Atlanta	Georgia	30322	Recruiting
Brigham and Women's Hospital	Boston	Massachusetts	02115	Recruiting
Michigan Medicine University of Michigan	Ann Arbor	Michigan	48109	Recruiting
Mayo Clinic	Rochester	Minnesota	55902	Recruiting
Roswell Park Cancer Institute	Buffalo	New York	14263	Recruiting
Columbia University Medical Center	New York	New York	10032	Recruiting
Duke Asthma, Allergy and Airway Center	Durham	North Carolina	27705	Recruiting
University of Cincinnati Medical Center	Cincinnati	Ohio	45219	Recruiting
The University of Texas, MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
Huntsman Cancer Institute, University of Utah	Salt Lake City	Utah	84112	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04910685, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 19, 2026 · Synced Apr 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04910685 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →